EMEA-000118-PIP01-07-M01
Key facts
| Invented name |
Orencia
|
| Active substance |
Abatacept
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/100/2009
|
| PIP number |
EMEA-000118-PIP01-07-M01
|
| Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-C-000118-PIP01-07-M01
|
| Compliance opinion date |
29/05/2009
|
| Compliance outcome |
positive
|